Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL-1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus.
Tim HeiseCharles DonnellyAbhijit BarvePatrick AubonnetPublished in: Diabetes, obesity & metabolism (2019)
Equivalence with regard to PK and PD characteristics was shown among MYL-1501D, US IG and EU IG in patients with T1DM, and each treatment was well tolerated and safe.
Keyphrases